Novavax saw the highest growth of 1.99% in patent filings in May and 2.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.28% and grants by 2.99%. GlobalData’s DataBook provides a comprehensive analysis of Novavax‘s patent filings and grants. Buy the databook here.
Novavax has been focused on protecting inventions in Australia(AU) with three publications in Q2 2024
The Australia(AU) Patent Office dominates the patent filings and grants with nearly 29% filings and 20% grants. The Australia(AU), World Intellectual Property Organization(WIPO), China(CN), and Japan(JP) patent Office are among the top ten patent offices where Novavax is filings its patents. Among the top granted patent authorities, Novavax has 20% of its grants in Australia(AU), 20% in China(CN) and 20% in Japan(JP).
GSK and Johnson & Johnson could be the strongest competitors for Novavax
Patents related to rare diseases and nanomedicine lead Novavax's portfolio
Novavax has the highest number of patents in rare diseases followed by, nanomedicine and Covid-19. For rare diseases, nearly 33% of patents were filed and no patents were granted in Q2 2024.
Severe acute respiratory syndrome (sars) related patents lead Novavax portfolio followed by respiratory syncytial virus (rsv) infections, and bacterial infections
Novavax has highest number of patents in severe acute respiratory syndrome (sars) followed by respiratory syncytial virus (rsv) infections, bacterial infections, malaria, and viral infections.
For comprehensive analysis of Novavax's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.